ArticleProstate cancer and prostatic diseases2024

PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer.

Tahlia Scheinberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.